TOKYO (Reuters) - Japan has approved the use of Gilead Sciences' drug "Remdesivir" to treat patients with coronavirus, as well as the country's official level of coronavirus treatment. Became the first certified drug.
The decision by Japan came just three days after the US pharmaceutical company filed a fast-track approval for the treatment.
"There is no cure for the coronavirus so far, so the approval of this medicine is an important step for us," a Japanese health ministry official said in a press briefing.
However, he also said that the remediator would be given to patients suffering from severe symptoms of coronavirus.
It is believed that there is a growing interest in medicine around the world due to the lack of an approved treatment for COVID 19.
And last week, the U.S. Food and Drug Administration approved its use as an emergency in the Novel Coronavirus.
Gilead Sciences said that the drug has had good results in people suffering from respiratory diseases and the data provided show that it can work even better if given in the early stages of the infection.
It should be noted that more than 16,000 cases and less than 800 deaths have been reported in Japan and fewer cases have been recorded here than in other major industrialized countries.
However, the growing number of cases has put pressure on medical facilities in some parts of the country, and a drug that helps patients recover faster can help clear hospital beds quickly.
A trial by the US Institute of Health (NIH) found that the drug reduced hospital stays by 31% compared to placebo treatment.
On Monday, Japanese Prime Minister Shinzo Abe extended the state of emergency until the end of May in a bid to curb the spread of the coronavirus.
The health ministry said Japan did not yet know when and how much of its first dose of remediation would be given.
It may be recalled that the American pharmaceutical company Glade Sciences had recently said that it was in talks with pharmaceutical companies in Pakistan and India to start production of the drug 'Remedivasor' which gives better results to patients with coronavirus. ۔
The remediator, which previously failed to treat Ebola, is designed to inactivate the replication of certain viruses inside infected cells.